Understanding how some leukaemia cells survive treatment and cause a relapse
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
A new way of treating poor prognosis Wilms’ tumour
Targeting gain of function p53 in poor prognosis Wilms' tumour via histone methyltransferase inhibition
Electrotherapy for childhood brain tumours
Electrotherapy for childhood brain tumours
Killing dormant leukaemia cells to stop relapse
Targeting refractory and dormant stem cells in childhood leukaemia
Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Understanding the biology of relapsed ependymoma brain tumours to help improve treatments
Deciphering the New Molecular Landscape in Paediatric Recurrent Ependymoma: Implications for Molecular Targeted Therapy
‘Starving’ brain tumours to death
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods
Phase II clinical trial: Can a new drug help treat relapsed or refractory (not responding to treatment) ALK+ anaplastic large cell lymphoma?
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers